Regulations.gov document
Recurrent Herpes Labialis: Developing Drugs for Treatment and Prevention Guidance for…
Other · FDA-2016-D-1504 · posted Jul 1, 2016
Key facts
| Document ID | FDA-2016-D-1504-0002 |
|---|---|
| Title | Recurrent Herpes Labialis: Developing Drugs for Treatment and Prevention Guidance for Industry DRAFT GUIDANCE |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2016-D-1504 |
| Posted | Jul 1, 2016 |
| Comment period opens | Jul 1, 2016 |
| Comments due | Sep 30, 2016 |
At a glance
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: